-
SAGE Open Medicine 2020The purpose of this study was to systematically review the literature as to the effects of performing exercise with a full versus partial range of motion (ROM) during... (Review)
Review
The purpose of this study was to systematically review the literature as to the effects of performing exercise with a full versus partial range of motion (ROM) during dynamic, longitudinal resistance training (RT) programs on changes in muscle hypertrophy. Based on the available literature, we aimed to draw evidence-based recommendations for RT prescription. Six studies were identified as meeting inclusion criteria: four of these studies involved RT for the lower limbs while the other two focused on the upper extremities. The total combined sample of the studies was = 135, which comprised 127 men and 8 women. The methodological quality of all included studies was deemed to be "excellent" based on the modified PEDro scale. When assessing the current body of literature, it can be inferred that performing RT through a full ROM confers beneficial effects on hypertrophy of the lower body musculature versus training with a partial ROM. Alternatively, research on the effects of ROM for the upper limbs is limited and conflicting, precluding the ability to draw strong practical inferences. No study to date has investigated how ROM influences muscle growth of the trunk musculature. Finally, some evidence indicates that the response to variations in ROM may be muscle-specific; however, this hypothesis also warrants further study.
PubMed: 32030125
DOI: 10.1177/2050312120901559 -
N-3 PUFA as an ergogenic supplement modulating muscle hypertrophy and strength: a systematic review.Critical Reviews in Food Science and... 2022There is growing evidence that suggests that n-3 polyunsaturated fatty acids (PUFA) may improve physical performance when combined with proper training through...
There is growing evidence that suggests that n-3 polyunsaturated fatty acids (PUFA) may improve physical performance when combined with proper training through modulation of muscle hypertrophy, muscle strength, and delayed onset muscle soreness (DOMS). This systematic review aims to examine the effect and optimal dosage of n-3 PUFA supplementation on muscle hypertrophy, muscle strength, and DOMS when combined with physical exercise. The PubMed, Web of Science, MEDLINE Complete, CINAHL and SPORTDiscus databases were searched following the PRISMA guidelines. Randomized controlled trials performed with healthy humans were considered. Fifteen studies with a total of 461 individuals were included in this systematic review. All of them measured muscle function (short physical performance test, range of motion (ROM), electromechanical delay (EMD), muscle echo intensity or muscle quality) and DOMS. Fourteen studies evaluated muscle strength and only six assessed muscle hypertrophy. Our results demonstrated that n-3 PUFA does not improve muscle hypertrophy, muscle strength or skeletal muscle biomarkers of inflammation and muscle damage beyond the benefits obtained by the training itself. Nevertheless, n-3 PUFA improves DOMS recovery and muscle function (measured by ROM, EMD and muscle quality).
Topics: Humans; Fatty Acids, Omega-3; Dietary Supplements; Myalgia; Muscle, Skeletal; Hypertrophy
PubMed: 34128440
DOI: 10.1080/10408398.2021.1939262 -
European Spine Journal : Official... Mar 2020There is anecdotal evidence that many patients who undergo reduction mammoplasty (RM) procedures, to relieve symptoms of large breasts, also report improvement in... (Meta-Analysis)
Meta-Analysis Review
PURPOSE
There is anecdotal evidence that many patients who undergo reduction mammoplasty (RM) procedures, to relieve symptoms of large breasts, also report improvement in existing back pain. Given how important back pain is as a healthcare burden, the literature which explores the relationship between RM and back pain is sparse. Thus, we aimed to appraise whether such a correlation exists, through systematic review and meta-analysis.
METHOD
Adhering to PRISMA methodology, we used the OVID engine to search the MEDLINE and Embase databases with predefined search terms and inclusion criteria. MeSH terms were not exploded. Statistical analysis was performed using Review Manager 5.3, employing a Mantell-Haenszel method and a fixed-effect model suitable for dichotomous data.
RESULTS
The review yielded 13 articles after exclusions, eight of which were suitable for quantitative analysis. The results of the analysis suggested an improvement in back pain following RM across all studies (OR 40.37 [8.09, 201.53] 95% CI, n = 1008). Heterogeneity was high (τ = 5.14, χ = 230.37, df = 7 (p < 0.00001) i = 97%).
CONCLUSIONS
Although cursory, the evidence gleaned suggests that RM reduces the prevalence of back pain in patients with large breasts. Furthermore, we highlight the scarcity of studies investigating whether RM is at the clinical threshold of efficacy in treating back pain. Although the evidence is insufficient for recommending RM as a management option aimed at treating back pain, this review does identify the need for prospective data looking at back pain metrics as a specific outcome measure before and after reduction mammoplasty.
Topics: Back Pain; Female; Humans; Hypertrophy; Low Back Pain; Mammaplasty; Prospective Studies
PubMed: 31606817
DOI: 10.1007/s00586-019-06155-2 -
Physiological Reports Sep 2020This study aimed to review the effects of ladder-based resistance training (LRT) on muscle hypertrophy and strength in rodents through a systematic review with... (Meta-Analysis)
Meta-Analysis
This study aimed to review the effects of ladder-based resistance training (LRT) on muscle hypertrophy and strength in rodents through a systematic review with meta-analysis. We systematically searched PubMed/Medline, SportDiscuss, Scopus, Google Scholar, Science Direct, and Scielo database on May 18, 2020. Thirty-four studies were included measuring total (mCSA) or mean muscle fibers cross-sectional area (fCSA) or maximum load-carrying capacity (MLCC) or muscle mass (MM). About the main results, LRT provides sufficient mechanical stimulation to increase mCSA and fCSA. Meta-analysis showed a significant overall effect on the fCSA (SMD 1.89, 95% CI [1.18, 2.61], p < .00001, I = 85%); however, subgroup analysis showed that some muscle types might not be hypertrophied through the LRT. Meta-analysis showed a significant training effect on the MM (SMD 0.92, 95% CI [0.52, 1.32], p < .00001, I = 72%). Sub-group analysis revealed that soleus (SMD 1.32, 95% CI [0.11, 2.54], p = .03, I = 86%) and FHL (SMD 1.92, 95% CI [1.00, 2.85], p < .0001, I = 71%) presented significant training effects, despite moderate heterogeneity levels (I = 72%). MLCC increases considerably after a period of LRT, regardless of its duration and the characteristics of the protocols (SMD 12.37, 95% CI [9.36, 15.37], p < .00001, I = 90%). Through these results, we reach the following conclusions: (a) LRT is efficient to induce muscle hypertrophy, although this effect varies between different types of skeletal muscles, and; (b) the ability of rodents to carry load increases regardless of the type and duration of the protocol used.
Topics: Animals; Hypertrophy; Mice; Muscle Strength; Muscle, Skeletal; Physical Conditioning, Animal; Rats
PubMed: 32889774
DOI: 10.14814/phy2.14502 -
Sports Medicine - Open Jan 2022Autoregulation has emerged as a potentially beneficial resistance training paradigm to individualize and optimize programming; however, compared to standardized...
BACKGROUND
Autoregulation has emerged as a potentially beneficial resistance training paradigm to individualize and optimize programming; however, compared to standardized prescription, the effects of autoregulated load and volume prescription on muscular strength and hypertrophy adaptations are unclear. Our objective was to compare the effect of autoregulated load prescription (repetitions in reserve-based rating of perceived exertion and velocity-based training) to standardized load prescription (percentage-based training) on chronic one-repetition maximum (1RM) strength and cross-sectional area (CSA) hypertrophy adaptations in resistance-trained individuals. We also aimed to investigate the effect of volume autoregulation with velocity loss thresholds ≤ 25% compared to > 25% on 1RM strength and CSA hypertrophy.
METHODS
This review was performed in accordance with the PRISMA guidelines. A systematic search of MEDLINE, Embase, Scopus, and SPORTDiscus was conducted. Mean differences (MD), 95% confidence intervals (CI), and standardized mean differences (SMD) were calculated. Sub-analyses were performed as applicable.
RESULTS
Fifteen studies were included in the meta-analysis: six studies on load autoregulation and nine studies on volume autoregulation. No significant differences between autoregulated and standardized load prescription were demonstrated for 1RM strength (MD = 2.07, 95% CI - 0.32 to 4.46 kg, p = 0.09, SMD = 0.21). Velocity loss thresholds ≤ 25% demonstrated significantly greater 1RM strength (MD = 2.32, 95% CI 0.33 to 4.31 kg, p = 0.02, SMD = 0.23) and significantly lower CSA hypertrophy (MD = 0.61, 95% CI 0.05 to 1.16 cm, p = 0.03, SMD = 0.28) than velocity loss thresholds > 25%. No significant differences between velocity loss thresholds > 25% and 20-25% were demonstrated for hypertrophy (MD = 0.36, 95% CI - 0.29 to 1.00 cm, p = 0.28, SMD = 0.13); however, velocity loss thresholds > 25% demonstrated significantly greater hypertrophy compared to thresholds ≤ 20% (MD = 0.64, 95% CI 0.07 to 1.20 cm, p = 0.03, SMD = 0.34).
CONCLUSIONS
Collectively, autoregulated and standardized load prescription produced similar improvements in strength. When sets and relative intensity were equated, velocity loss thresholds ≤ 25% were superior for promoting strength possibly by minimizing acute neuromuscular fatigue while maximizing chronic neuromuscular adaptations, whereas velocity loss thresholds > 20-25% were superior for promoting hypertrophy by accumulating greater relative volume. Protocol Registration The original protocol was prospectively registered (CRD42021240506) with the PROSPERO (International Prospective Register of Systematic Reviews).
PubMed: 35038063
DOI: 10.1186/s40798-021-00404-9 -
Cureus Nov 2022Otitis media with effusion (OME) affects approximately 80% of children due to the middle ear being flooded with fluids, though with no microbial infection... (Review)
Review
Otitis media with effusion (OME) affects approximately 80% of children due to the middle ear being flooded with fluids, though with no microbial infection manifestations. Multiple issues can drive recurring pediatric OME, such as environment-based issues, previous medical issues, inherited vulnerability from family, contact time at childcare institutes, passive smoking, and more than three siblings together with atopy or allergic rhinitis. If OME is not promptly addressed, this could eventually result in hearing impairment or loss, with consequent negative repercussions on the child's communicative and behavioral patterns. OME diagnosis within the clinic is possible, with hearing capacity being assessed pre- and post-therapy. Adenoid hypertrophy (AH) represents a typical causative factor for middle-ear conditions, stemming from mechanical or anatomical issues. Consequently, adenoid size is paramount when determining tympanometry types and ear fluids. This systematic review investigated PubMed, Medline, Cochrane Library, and Science Direct databases in order to retrieve knowledge related to this issue, adopting inclusion and exclusion criteria and maintaining review quality through the employment of the Assessment of Multiple Systematic Reviews (AMSTAR), the Newcastle-Ottawa tool, and the Axis scale. This systematic review analyzed a previous review article, six observation-based investigations, and three cross-sectional investigations. Previous randomized controlled trials (RCTs) were not found within previous literature, suggesting such scarcity in this research niche and thus warranting future RCT investigations based on this compelling research niche.
PubMed: 36465218
DOI: 10.7759/cureus.30985 -
Circulation. Genomic and Precision... Dec 2023The diagnosis of Fabry disease (FD) has relevant implications related to the management. Thus, a clear assignment of variant pathogenicity is crucial. This systematic... (Meta-Analysis)
Meta-Analysis
BACKGROUND
The diagnosis of Fabry disease (FD) has relevant implications related to the management. Thus, a clear assignment of variant pathogenicity is crucial. This systematic review and meta-analysis aimed to investigate the prevalence of FD in high-risk populations and newborns and evaluate the impact of different variant classifications on the estimated prevalence of FD.
METHODS
We searched the EMBASE and PubMed databases on February 21, 2023. Observational studies evaluating the prevalence of FD and reporting the identified variants were included. variants were re-evaluated for their pathogenicity significance using the American College of Medical Genetics and Genomics criteria and the ClinVar database. The pooled prevalence of FD among different settings was calculated. The study was registered on PROSPERO (CRD42023401663) and followed the Preferred Reporting Items for Systematic Reviews and Meta-Analysis guidelines.
RESULTS
Of the 3941 studies identified, 110 met the inclusion criteria. The pooled prevalence of FD was significantly different according to the clinical setting and criteria used for the pathogenicity assessment. Using the American College of Medical Genetics and Genomics criteria, the pooled prevalence was 1.2% in patients with left ventricular hypertrophy/hypertrophic cardiomyopathy (26 studies; 10 080 patients screened), 0.3% in end-stage renal disease/chronic kidney disease (38 studies; 62 050 patients screened), 0.7% in stroke (25 studies; 15 295 patients screened), 0.7% in cardiac conduction disturbance requiring pacemaker (3 studies; 1033 patients screened), 1.0% in small-fiber neuropathy (3 studies; 904 patients screened), and 0.01% in newborns (15 studies; 11 108 793 newborns screened). The pooled prevalence was different if the variants were assessed using the ClinVar database, and most patients with a discrepancy in the pathogenicity assignment carried 1 of the following variants: p.A143T, p.D313Y, and p.E66Q.
CONCLUSIONS
This systematic review and meta-analysis describe the prevalence of FD among newborns and high-risk populations, highlighting the need for a periodic reassessment of the variants in the context of recent clinical, biochemical, and histological data.
REGISTRATION
URL: https://crd.york.ac.uk/PROSPERO/; Unique identifier: CRD42023401663.
Topics: Humans; Infant, Newborn; Fabry Disease; alpha-Galactosidase; Prevalence; Hypertrophy, Left Ventricular; Stroke
PubMed: 38047356
DOI: 10.1161/CIRCGEN.123.004252 -
Vascular Pharmacology Nov 2018A systematic review and meta-analysis was performed to test candidate therapeutic approaches in pulmonary hypertension (PH). The efficacy of 522 interventions with >200... (Meta-Analysis)
Meta-Analysis Review
A systematic review and meta-analysis was performed to test candidate therapeutic approaches in pulmonary hypertension (PH). The efficacy of 522 interventions with >200 unregistered drugs was tested on 7254 animals. We propose a modified formula to assess meta-data that concerns the contribution of PH animal model to the denoted efficacy of tested agents. The measure of efficacy expressed as a response ratio for right ventricle systolic pressure was 0.48 (95% CI, 0.46-0.50; P < 0.00001), mean pulmonary artery pressure was 0.54 (0.52-0.56; P < 0.00001), right ventricle hypertrophy was 0.49 (0.48-0.51; P < 0.00001) and pulmonary artery wall thickness was 0.58 (0.56-0.61; P < 0.00001). Only 41 out of 522 interventions were ineffective. The most potent agents to improve both haemodynamic and hypertrophic parameters were ATP-sensitive potassium channel openers with iptakalim, Rho/ROCK inhibitors with fasudil, RAAS regulators with adenosine and ACE2 activators, and anti-inflammatories with n-3 polyunsaturated fatty acids and NF-кB inhibitors.
Topics: Animals; Antihypertensive Agents; Arterial Pressure; Disease Models, Animal; Hypertension, Pulmonary; Hypertrophy, Right Ventricular; Molecular Targeted Therapy; Pulmonary Artery; Signal Transduction; Vascular Remodeling; Ventricular Function, Right; Ventricular Remodeling
PubMed: 30145225
DOI: 10.1016/j.vph.2018.08.004 -
Plastic and Reconstructive Surgery Sep 2016Inferior turbinate hypertrophy is often encountered by plastic surgeons who perform rhinoplasty. Many treatment options are available to treat the inferior turbinate.... (Comparative Study)
Comparative Study Review
BACKGROUND
Inferior turbinate hypertrophy is often encountered by plastic surgeons who perform rhinoplasty. Many treatment options are available to treat the inferior turbinate. The objective of this study was to systematically review outcomes of available techniques and provide guidance to surgical turbinate management.
METHODS
A MEDLINE search was performed for means of treating inferior turbinate hypertrophy. Studies selected focused on treatment of the inferior turbinate in isolation and excluding patients with refractory allergic rhinitis, vasomotor rhinitis, or hypertrophic rhinitis.
RESULTS
Fifty-eight articles were identified, collectively including the following surgical treatments of inferior turbinate hypertrophy: total turbinectomy, partial turbinectomy, submucosal resection, laser surgery, cryotherapy, electrocautery, radiofrequency ablation, and turbinate outfracture. Outcomes and complications were collected from all studies. Procedures such as turbinectomy (partial/total) and submucosal resection showed crusting and epistaxis at comparatively higher rates, whereas more conservative treatments such as cryotherapy and submucous diathermy failed to provide long-term results. Submucosal resection and radiofrequency ablation were shown to decrease nasal resistance and preserve mucosal function. No literature exists to support the belief that turbinate outfracture alone is an effective treatment for turbinate hypertrophy.
CONCLUSIONS
Treatment of inferior turbinate hypertrophy is best accomplished with modalities that provide long-lasting results, preservation of turbinate function, and low complication rates. Submucosal resection and radiofrequency ablation appear to best fulfill these criteria. Turbinate outfracture should only be considered in combination with tissue-reduction procedures.
Topics: Catheter Ablation; Cryotherapy; Humans; Hypertrophy; Outcome and Process Assessment, Health Care; Rhinoplasty; Turbinates
PubMed: 27556616
DOI: 10.1097/PRS.0000000000002433 -
Archives of Dermatological Research Sep 2023Exaggerated healing and remodeling after skin injury may cause hypertrophic and keloidal scars, which are associated with functional and quality of life impairment.... (Review)
Review
Exaggerated healing and remodeling after skin injury may cause hypertrophic and keloidal scars, which are associated with functional and quality of life impairment. There is limited guidance available regarding the relative effectiveness of therapies for hypertrophic scars and keloids. In this review, we aim to compare the effectiveness of treatments for hypertrophic scars and keloids. MEDLINE, Embase, Scopus, and the Cochrane Collaboration database were searched from inception to March 2019 for randomized control trials of treatments for hypertrophic and keloid scars that included 20 or more patients. Outcomes evaluated included the standardized mean reduction in scarring and adverse events. The type of scar and the demographic features were analyzed for their effect on clinical outcome. Based on 25 included clinical trials, intralesional injection (64.1% [95% CI 60.8-67.5%]) may be more effective than physical (29.9% [95% CI 28.9-30.9%]) or topical treatments (34% [95% CI 31.8-36.8%]). Combination of 5-fluorouracil and triamcinolone (9:1 dilution) appeared superior among intralesional treatments for keloids. Ablative laser and pulsed-dye laser were the most useful laser treatments. Regression modeling showed laser treatment response was linked to Fitzpatrick skin type (p = 0.002). Adverse events were uncommon for all treatments and mostly transient. Intralesional treatments for keloid and hypertrophic scars may be the most reliable treatment option to improve pathologic scars, while laser treatment may have specific benefits for Fitzpatrick skin types I-III over types IV-VI. Management of pathological scars is an area of critical need, where appropriate treatment can have a significant impact on quality of life.
Topics: Humans; Keloid; Cicatrix, Hypertrophic; Quality of Life; Hypertrophy; Fluorouracil; Treatment Outcome; Injections, Intralesional
PubMed: 36781457
DOI: 10.1007/s00403-023-02535-3